Clinical Updates in Treating Advanced Prostate Cancer

Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.

EP. 1: Treatment Landscape and Sequencing of Therapies

September 30th 2024

Panelists discuss how advancements in biomarker and genetic testing, along with updated treatment guidelines, are transforming the diagnosis and management of prostate cancer, emphasizing the importance of personalized approaches in optimizing patient outcomes.

EP. 2: Treatment Timelines Related to Disease State and Use of Monotherapy

September 30th 2024

Panelists discuss the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC), exploring main therapeutic approaches, the role of androgen deprivation monotherapy, the timing for adding chemotherapy and ARPIs, and strategies for sequencing or combining these modalities in clinical practice.

EP. 3: Genetic Testing – Germline

October 7th 2024

Panelists discuss how genetic testing for germline mutations is becoming increasingly crucial in the management of prostate cancer, enabling personalized treatment approaches and informing patient care decisions.

EP. 4: Recent Data on ARPI-Based Combination Regimens

October 7th 2024

Panelists discuss how recent data on androgen receptor pathway inhibitor–based combination regimens highlight their potential to enhance treatment outcomes for advanced prostate cancer, underscoring the importance of integrating these findings into clinical practice.

EP. 5: Genetic Testing – Somatic

October 14th 2024

Panelists discuss how somatic genetic testing is essential for identifying actionable mutations in prostate cancer, guiding targeted therapies, and improving treatment outcomes for patients.

EP. 6: ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

October 14th 2024

Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.